Use of Alcalase in the production of bioactive peptides: A review
This review aims to cover the uses of the commercially available protease Alcalase in the production of biologically active peptides since 2010. Immobilization of Alcalase has also been reviewed, as immobilization of the enzyme may improve the final reaction design enabling the use of more drastic conditions and the reuse of the biocatalyst.
That way, this review presents the production, via Alcalase hydrolysis of different proteins, of peptides with antioxidant, angiotensin I-converting enzyme inhibitory, metal binding, antidiabetic, anti-inflammatory and antimicrobial activities (among other bioactivities) and peptides that improve the functional, sensory and nutritional properties of foods.
Alcalase has proved to be among the most efficient proteases for this goal, using different protein sources, being especially interesting the use of the protein residues from food industry as feedstock, as this also solves nature pollution problems.
Very interestingly, the bioactivities of the protein hydrolysates further improved when Alcalase is used in a combined way with other proteases both in a sequential way or in a simultaneous hydrolysis (something that could be related to the concept of combi-enzymes), as the combination of proteases with different selectivities and specificities enable the production of a larger amount of peptides and of a smaller size.
Development of A2G80 peptide-gene complex for targeted delivery to muscle cells
Therapeutic strategies based on antisense oligonucleotides and therapeutic genes are being extensively investigated for the treatment of hereditary muscle diseases and hold great promise. However, the cellular uptake of these polyanions to the muscle cells is inefficient. Therefore, it is necessary to develop more effective methods of gene delivery into the muscle tissue.
- The A2G80 peptide (VQLRNGFPYFSY) from the laminin α2 chain has high affinity for α-dystroglycan (α-DG) which is expressed on the membrane of muscle cells. In this study, we designed a peptide-modified A2G80 with oligoarginine and oligohistidine (A2G80-R9-H8), and prepared peptide/plasmid DNA (pDNA) complex, to develop an efficient gene delivery system for the muscle tissue.
- The peptide/pDNA complex showed α-DG-dependent cellular uptake of the A2G80 sequence and significantly improved gene transfection efficiency mediated by the oligohistidine sequence in C2C12 myoblast cells. Further, the peptide/pDNA complex promoted efficient and sustained gene expression in the Duchenne muscular dystrophy mouse models. The A2G80-R9-H8 peptide has the potential for use as a specific carrier for targeting muscle in gene therapy in muscular dystrophy.
Synthetic peptide hydrogels as 3D scaffolds for tissue engineering
The regeneration of tissues and organs poses an immense challenge due to the extreme complexity in the research work involved. Despite the tissue engineering approach being considered as a promising strategy for more than two decades, a key issue impeding its progress is the lack of ideal scaffold materials.
Nature-inspired synthetic peptide hydrogels are inherently biocompatible, and its high resemblance to extracellular matrix makes peptide hydrogels suitable 3D scaffold materials. This review covers the important aspects of peptide hydrogels as 3D scaffolds, including mechanical properties, biodegradability and bioactivity, and the current approaches in creating matrices with optimized features. Many of these scaffolds contain peptide sequences that are widely reported for tissue repair and regeneration and these peptide sequences will also be discussed.
Furthermore, 3D biofabrication strategies of synthetic peptide hydrogels and the recent advances of peptide hydrogels in tissue engineering will also be described to reflect the current trend in the field. In the final section, we will present the future outlook in the design and development of peptide-based hydrogels for translational tissue engineering applications.
Study of the Interaction of a Novel Semi-Synthetic Peptide with Model Lipid Membranes
- Most linear peptides directly interact with membranes, but the mechanisms of interaction are far from being completely understood. Here, we present an investigation of the membrane interactions of a designed peptide containing a non-natural, synthetic amino acid. We selected a nonapeptide that is reported to interact with phospholipid membranes, ALYLAIRKR, abbreviated as ALY.
- We designed a modified peptide (azoALY) by substituting the tyrosine residue of ALY with an antimicrobial azobenzene-bearing amino acid. Both of the peptides were examined for their ability to interact with model membranes, assessing the penetration of phospholipid monolayers, and leakage across the bilayer of large unilamellar vesicles (LUVs) and giant unilamellar vesicles (GUVs).
- The latter was performed in a microfluidic device in order to study the kinetics of leakage of entrapped calcein from the vesicles at the single vesicle level. Both types of vesicles were prepared from a 9:1 (mol/mol) mixture of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho(1′-rac-glycerol). Calcein leakage from the vesicles was more pronounced at a low concentration in the case of azoALY than for ALY.
- Increased vesicle membrane disturbance in the presence of azoALY was also evident from an enzymatic assay with LUVs and entrapped horseradish peroxidase. Molecular dynamics simulations of ALY and azoALY in an anionic POPC/POPG model bilayer showed that ALY peptide only interacts with the lipid head groups.
- In contrast, azoALY penetrates the hydrophobic core of the bilayers causing a stronger membrane perturbation as compared to ALY, in qualitative agreement with the experimental results from the leakage assays.
Glypican 6 protein (His tag) |
MBS5304221-5x01mg |
MyBiosource |
5x0.1mg |
EUR 10470 |
Human Glypican-6 (GPC6) |
1-CSB-YP009708HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human Glypican-6(GPC6) expressed in Yeast |
Human Glypican-1 (GPC1) Protein |
abx060282-100ug |
Abbexa |
100 ug |
EUR 944.4 |
|
Human Glypican-1 (GPC1) Protein |
abx060282-100g |
Abbexa |
100 µg |
Ask for price |
Human Glypican-1 (GPC1) Protein |
abx060282-10g |
Abbexa |
10 µg |
EUR 700 |
Human Glypican-1 (GPC1) Protein |
abx060282-50g |
Abbexa |
50 µg |
Ask for price |
Human Glypican-1 (GPC1) Protein |
abx694143-10nmol |
Abbexa |
10 nmol |
EUR 400 |
Human Glypican-1 (GPC1) Protein |
abx694143-5nmol |
Abbexa |
5 nmol |
EUR 300 |
Recombinant Human Glypican 3 Protein |
MBS9141716-002mg |
MyBiosource |
0.02mg |
EUR 195 |
Recombinant Human Glypican 3 Protein |
MBS9141716-005mg |
MyBiosource |
0.05mg |
EUR 255 |
Recombinant Human Glypican 3 Protein |
MBS9141716-01mg |
MyBiosource |
0.1mg |
EUR 335 |
Recombinant Human Glypican 3 Protein |
MBS9141716-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1330 |
Recombinant Human Glypican 1 Protein |
MBS9141834-002mg |
MyBiosource |
0.02mg |
EUR 195 |
Recombinant Human Glypican 1 Protein |
MBS9141834-005mg |
MyBiosource |
0.05mg |
EUR 255 |
Recombinant Human Glypican 1 Protein |
MBS9141834-01mg |
MyBiosource |
0.1mg |
EUR 335 |
Recombinant Human Glypican 1 Protein |
MBS9141834-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1330 |
Recombinant Human Glypican 1 Protein |
MBS8305000-001mg |
MyBiosource |
0.01mg |
EUR 235 |
Recombinant Human Glypican 1 Protein |
MBS8305000-005mg |
MyBiosource |
0.05mg |
EUR 510 |
Recombinant Human Glypican 1 Protein |
MBS8305000-05mg |
MyBiosource |
0.5mg |
EUR 2375 |
Recombinant Human Glypican 1 Protein |
MBS8305000-5x05mg |
MyBiosource |
5x0.5mg |
EUR 10585 |
Recombinant Human Glypican-6 |
MBS1190971-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 255 |
Recombinant Human Glypican-6 |
MBS1190971-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 270 |
Recombinant Human Glypican-6 |
MBS1190971-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 405 |
Recombinant Human Glypican-6 |
MBS1190971-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 450 |
Recombinant Human Glypican-6 |
MBS1190971-1mgEColi |
MyBiosource |
1mg(E-Coli) |
EUR 1425 |
Recombinant Human Glypican-6 |
MBS9422309-002mg |
MyBiosource |
0.02mg |
EUR 320 |
Recombinant Human Glypican-6 |
MBS9422309-01mg |
MyBiosource |
0.1mg |
EUR 540 |
Recombinant Human Glypican-6 |
MBS9422309-1mg |
MyBiosource |
1mg |
EUR 2070 |
Recombinant Human Glypican-6 |
MBS9422309-5x1mg |
MyBiosource |
5x1mg |
EUR 9160 |
Human Glypican 1 (GPC1) Protein |
20-abx066889 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glypican 3 (GPC3) Protein |
20-abx066892 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glypican 4 (GPC4) Protein |
20-abx066893 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glypican 3 (GPC3) Protein |
abx060155-100ug |
Abbexa |
100 ug |
EUR 1362 |
|
Human Glypican 3 (GPC3) Protein |
abx060263-1mg |
Abbexa |
1 mg |
EUR 2532 |
|
Human Glypican 2 (GPC2) Protein |
20-abx653616 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glypican 3 (GPC3) Protein |
abx060155-100g |
Abbexa |
100 µg |
Ask for price |
Human Glypican 3 (GPC3) Protein |
abx060155-10g |
Abbexa |
10 µg |
EUR 1037.5 |
Human Glypican 3 (GPC3) Protein |
abx060155-50g |
Abbexa |
50 µg |
EUR 2987.5 |
Human Glypican 3 (GPC3) Protein |
abx060263-100g |
Abbexa |
100 µg |
Ask for price |
Human Glypican 3 (GPC3) Protein |
abx060263-10g |
Abbexa |
10 µg |
EUR 1975 |
Human Glypican 3 (GPC3) Protein |
abx060263-50g |
Abbexa |
50 µg |
Ask for price |
Human Glypican 1 (GPC1) Protein |
abx066889-100g |
Abbexa |
100 µg |
EUR 425 |
Human Glypican 1 (GPC1) Protein |
abx066889-10g |
Abbexa |
10 µg |
EUR 187.5 |
Human Glypican 1 (GPC1) Protein |
abx066889-50g |
Abbexa |
50 µg |
EUR 300 |
Human Glypican 3 (GPC3) Protein |
abx066892-100g |
Abbexa |
100 µg |
EUR 512.5 |
Human Glypican 3 (GPC3) Protein |
abx066892-10g |
Abbexa |
10 µg |
EUR 212.5 |
Human Glypican 3 (GPC3) Protein |
abx066892-50g |
Abbexa |
50 µg |
EUR 362.5 |
Human Glypican 4 (GPC4) Protein |
abx066893-100g |
Abbexa |
100 µg |
EUR 625 |
Human Glypican 4 (GPC4) Protein |
abx066893-10g |
Abbexa |
10 µg |
EUR 237.5 |
Human Glypican 4 (GPC4) Protein |
abx066893-50g |
Abbexa |
50 µg |
EUR 425 |
Human Glypican 2 (GPC2) Protein |
abx653616-100g |
Abbexa |
100 µg |
EUR 1800 |
Human Glypican 3 (GPC3) Protein |
abx680130-10g |
Abbexa |
10 µg |
EUR 225 |
Human Glypican 3 (GPC3) Protein |
abx680130-50g |
Abbexa |
50 µg |
EUR 325 |
Human Glypican 5 (GPC5) Protein |
abx691793-100g |
Abbexa |
100 µg |
EUR 837.5 |
Human Glypican 5 (GPC5) Protein |
abx691793-1mg |
Abbexa |
1 mg |
Ask for price |
Glypican 6, Recombinant, Human (Glypiated Proteoglycan 6) |
MBS637975-005mg |
MyBiosource |
0.05mg |
EUR 940 |
Glypican 6, Recombinant, Human (Glypiated Proteoglycan 6) |
MBS637975-5x005mg |
MyBiosource |
5x0.05mg |
EUR 4080 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS9304706-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS9304706-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS9304706-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS9304706-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS165463-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3460 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS165463-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 285 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS165463-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 1750 |
Human Glypican-6, GPC-6 ELISA Kit |
MBS165463-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 425 |
Human Glypican 3 Protein (Gln 25-His 559) |
VAng-1696Lsx-100g |
Creative Biolabs |
100 µg |
EUR 1116 |
Description: Human Glypican 3 (GPC3) is expressed in human 293 cells. (Uniprot ID: P51654-1) |
Human Glypican 3 Protein (Gln 25-His 559) |
VAng-1696Lsx-1mg |
Creative Biolabs |
1 mg |
EUR 5998.8 |
Description: Human Glypican 3 (GPC3) is expressed in human 293 cells. (Uniprot ID: P51654-1) |
Human Glypican 6 ELISA kit |
E01A4951 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Recombinant Human Glypican 3 Protein, His Tag |
E40KMP1201 |
EnoGene |
20ug |
EUR 495 |
Recombinant Human Glypican 1 Protein, His Tag |
E40KMP1589 |
EnoGene |
20ug |
EUR 495 |
Recombinant Human Glypican-6 (GPC6) |
CSB-YP009708HU |
Cusabio |
5689 mg |
Ask for price |
Recombinant Human Glypican-6(GPC6) |
AP72579 |
SAB |
1mg |
EUR 2303 |
|
Recombinant Human Glypican-6 (GPC6) |
CSB-EP009708HU |
Cusabio |
1297 mg |
Ask for price |
Recombinant Human Glypican-6 (GPC6) |
MBS1312042-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1370 |
Recombinant Human Glypican-6 (GPC6) |
MBS1312042-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 1075 |
Recombinant Human Glypican-6 (GPC6) |
MBS1312042-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 1130 |
Recombinant Human Glypican-6 (GPC6) |
MBS1312042-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 1255 |
Recombinant Human Glypican-6 (GPC6) |
MBS1312042-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1330 |
Human GPC-6 (Glypican-6) ELISA Kit |
MBS7614949-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3900 |
Human GPC-6 (Glypican-6) ELISA Kit |
MBS7614949-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 340 |
Human GPC-6 (Glypican-6) ELISA Kit |
MBS7614949-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2045 |
Human GPC-6 (Glypican-6) ELISA Kit |
MBS7614949-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 455 |
Human Glypican-6, GPC-6 GENLISA ELISA |
KBH3115 |
Krishgen |
1 x 96 wells |
EUR 286 |
Human Glypican 2 Protein (Ser 24-Gly 554) [Fc] |
VAng-1694Lsx-100g |
Creative Biolabs |
100 µg |
EUR 1215.6 |
Description: Human Glypican 2 (GPC2), Fc Tag, is expressed in human 293 cells. (Uniprot ID: Q8N158-1) |
Maintenance and differentiation of human ES cells on polyvinylidene fluoride scaffolds immobilized with a vitronectin-derived peptide
Polyvinylidene fluoride (PVDF) is biocompatible, easy to fabricate, and has piezoelectric properties; it has been used for many biomedical applications including stem cell engineering. However, long-term cultivation of human embryonic stem cells (hESCs) and their differentiation toward cardiac lineages on PVDF have not been investigated.
Herein, PVDF nanoscaled membrane scaffolds were fabricated by electrospinning; a vitronectin-derived peptide-mussel adhesive protein fusion (VNm) was immobilized on the scaffolds. hESCs cultured on the VNm-coated PVDF scaffold (VNm-PVDF scaffold) were stably expanded for more than 10 passages while maintaining the expression of pluripotency markers and genomic integrity.
Under cardiac differentiation conditions, hESCs on the VNm-PVDF scaffold generated more spontaneously beating colonies and showed the upregulation of cardiac-related genes, compared with those cultured on Matrigel and VNm alone. Thus, VNm-PVDF scaffolds may be suitable for the long-term culture of hESCs and their differentiation into cardiac cells, thus expanding their application in regenerative medicine.